Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

RxSight Raises FY2025 Sales Guidance from $120.000M-$130.000M to $125.000M-$130.000M vs $125.489M Est

Author: Benzinga Newsdesk | November 05, 2025 04:20pm
RxSight (NASDAQ:RXST) raises FY2025 sales outlook from $120.000 million-$130.000 million to $125.000 million-$130.000 million vs $125.489 million estimate.

Posted In: RXST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist